Your browser doesn't support javascript.
loading
World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease.
Saketkoo, Lesley Ann; Escorpizo, Reuben; Varga, Janos; Keen, Kevin John; Fligelstone, Kim; Birring, Surinder S; Alexanderson, Helene; Pettersson, Henrik; Chaudhry, Humza Ahmad; Poole, Janet L; Regardt, Malin; LeSage, Daphne; Sarver, Catherine; Lanario, Joseph; Renzoni, Elisabetta; Scholand, Mary Beth; Lammi, Matthew R; Kowal-Bielecka, Otylia; Distler, Oliver; Frech, Tracy; Shapiro, Lee; Varju, Cecilia; Volkmann, Elizabeth R; Bernstein, Elana J; Drent, Marjolein; Obi, Ogugua Ndili; Patterson, Karen C; Russell, Anne-Marie.
Affiliation
  • Saketkoo LA; New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, United States.
  • Escorpizo R; University Medical Center-Comprehensive Pulmonary Hypertension Center & Interstitial Lung Disease Clinic Programs, New Orleans, LA, United States.
  • Varga J; Tulane University School of Medicine, New Orleans, LA, United States.
  • Keen KJ; Louisiana State University Health Sciences Center, Division of Pulmonary Medicine-New Orleans, New Orleans, LA, United States.
  • Fligelstone K; Department of Rehabilitation and Movement Science, The University of Vermont, Burlington, VT, United States.
  • Birring SS; Swiss Paraplegic Research, Nottwil, Switzerland.
  • Alexanderson H; Department of Pulmonology, Semmelweis University, Budapest, Hungary.
  • Pettersson H; Department of Mathematics and Statistics and Health Research Institute, University of Northern British Columbia, Prince George, BC, Canada.
  • Chaudhry HA; Department of Medicine, University of British Columbia & Centre for Heart Lung Innovation, Providence Research, Vancouver, BC, Canada.
  • Poole JL; Patient Research Partner Scleroderma & Raynaud Society, UK (SRUK) and Federation of European Scleroderma Associations, London, United Kingdom.
  • Regardt M; Royal Free Hospital Scleroderma Unit, London, United Kingdom.
  • LeSage D; Division of Asthma, Allergy and Lung Biology, King's College London, London, United Kingdom.
  • Sarver C; Women's Health and Allied Health Professionals, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden.
  • Lanario J; Department of Medicin, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden.
  • Renzoni E; Women's Health and Allied Health Professionals, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden.
  • Scholand MB; Department of Medicin, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden.
  • Lammi MR; New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, United States.
  • Kowal-Bielecka O; University Medical Center-Comprehensive Pulmonary Hypertension Center & Interstitial Lung Disease Clinic Programs, New Orleans, LA, United States.
  • Distler O; Tulane University School of Medicine, New Orleans, LA, United States.
  • Frech T; Occupational Therapy Graduate Program, University of New Mexico, Albuquerque, NM, United States.
  • Shapiro L; Women's Health and Allied Health Professionals, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden.
  • Varju C; Department of Medicin, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden.
  • Volkmann ER; Patient Research Partner, New Orleans, LA, United States.
  • Bernstein EJ; Patient Research Partner, Baltimore, MD, United States.
  • Drent M; Research Fellow in Respiratory Health-Exeter Respiratory Institute Royal Devon University Hospitals NHS Foundation Trust, Exeter, United Kingdom.
  • Obi ON; Royal Brompton Hospital, National Heart and Lung Institute, London, United Kingdom.
  • Patterson KC; Pulmonary Medicine, University of Utah, Salt Lake City, UT, United States.
  • Russell AM; New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, United States.
Front Pharmacol ; 13: 979788, 2022.
Article in En | MEDLINE | ID: mdl-36313333
ABSTRACT

Background:

The World Health Organization (WHO) introduced the International Classification of Functioning, Disability, and Health (ICF) as a scientific method of disability data collection comprised of >1,200 categories describing the spectrum of impairment types (functional, symptoms-based and anatomical) under the bio-psycho-social model with consideration of environmental and personal factors (pf). ICF Core Sets and ICF Checklists are streamlined disease-specific resources for clinical use, service provision, and for use in health economics and health policy. ICF can disclose strengths and weaknesses across multiple patient-reported outcome measures (PROMs) and help consolidate best-fitting question-items from multiple PROMs. Interstitial lung diseases (ILDs), are generally progressive, with restrictive physiology sometimes occurring in the context of multi-organ autoimmunity/inflammatory conditions such as connective tissue diseases (CTDs). In spite of significant associated morbidity and potential disability, ILD has yet to be linked to the ICF.

Methods:

Each instrument and their question-items within the consensus-recommended core sets for clinical trials in ILD were deconstructed to single concept units, and then linked per updated ICF linkage rules. Inter-linker agreement was established. Three additional subsequently validated measures were also included.

Results:

One-hundred-eleven ICF categories were identified for ten PROMs and three traditional objective measures that were amenable to ICF linkage. The proportion of agreement ranged from 0.79 (95% CI 0.62, 0.91) to 0.93 (0.76, 0.99) with the overall proportion of inter-linker agreement being very high 0.86 (0.82, 0.89) for the initial instruments, with 94-100% for the three additional PROMs. Thirty-four new 'Personal Factors' emerged to capture disease-specific qualities not elsewhere described in ICF, e.g. 'pf_embarrassed by cough' or 'pf_panic/afraid when can't get a breath'.

Conclusion:

This first known effort in ICF linkage of ILD has provided important revelations on the current utility of the ICF in lung disease. Results have indicated areas for meaningful assessment of ICF descriptors for lung impairment. The mapping across PROMs provides insight into possibilities of developing more streamline and precise instrumentation. Finally, familiarity with the ICF in ILD may enable clinicians to experience a smoother transition with the imminent harmonization of ICD and ICF, ICD-11.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Aspects: Patient_preference Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Aspects: Patient_preference Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: United States